Oppenheimer analyst Justin Kim raised the firm’s price target on Immunocore to $75 from $72 and keeps an Outperform rating on the shares. Immunocore announced plans to initiate a Phase 3 1L melanoma for IMC-F106C following a review of the ongoing experience coupled with platform, and the firm continues to appreciate the breadth of experience accrued from tebentafusp through IMC-F106C, which could see a first indication for the drug in the 2027+ timeframe, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMCR:
- Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
- Immunocore reports Q2 EPS (37c), consensus (41c)
- Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
- Immunocore initiated with a Hold at Canaccord on ‘modest’ near-term growth
- Immunocore initiated with a Hold at Canaccord